3/5
06:21 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
3/1
11:47 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/29
02:34 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
2/29
01:36 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/29
01:09 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
2/29
01:09 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
2/29
12:47 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/29
12:47 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/29
12:08 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/29
12:08 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/29
08:27 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
2/29
08:27 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
2/29
07:52 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
2/29
07:52 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
2/20
11:05 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/20
09:15 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
2/20
09:15 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $224.00 price target on the stock.
2/20
08:50 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/20
08:50 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/16
01:34 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/16
01:34 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/15
09:14 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/14
09:49 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/14
09:49 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/14
09:11 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.